PURPOSE:

To provide an overview of existing whole disease models (WDMs) and pathway models worldwide and discuss the benefits and risks of using those models from the perspective of academia, regulator and industry.

DESCRIPTION:

WDMs and pathway models are large-scale, system-level models which can evaluate multiple decision questions across an entire care pathway. Whilst these models can offer several advantages as a platform for undertaking economic analyses, the development of a WDM requires a significant initial investment of time and resources and presents additional challenges for model verification and validation. This workshop will bring together key experts from different sectors to discuss the benefits of risks of using WDMs and pathway models for academia, regulators and industry.

Workshop structure

• Presentation One (12 minutes): PT will give an introduction to WDM and pathway models and discuss the pilot work of applying those modelling approach to NICE clinical guidelines.
• Presentation Two (12 minutes): HJ will provide an overview of existing WDMs and pathway models worldwide and discuss the reusability of those models.
• Presentation Three (12 minutes): JC will discuss the benefits and risks of using WDMs and pathway models in the industry, using three models developed by Evidera as case studies.
• Discussion (12 minutes): PC will lead the discussion, drawing on his experiences of developing, updating and adapting the UKPDS model to different countries.

Stakeholders likely to benefit from attending the workshop

• Health economic modellers, or commissioners of health economics models, who need to evaluate multiple decision questions across the entire care pathway of a given disease, or stakeholders who are interested in reusing/adapting existing models.
• Health policy makers and commissioners who would like to adopt a whole system approach by moving resources from treatment to prevention and early intervention and moving resources from hospital to community.